August 2026 Research Update

Across these papers, research in autoimmune hemolytic anemia (AIHA) is testing treatments that act earlier in the immune process, either by lowering harmful antibodies in the blood or by blocking complement (a part of the immune system that can damage red blood cells). The strongest evidence here comes from a randomized trial in warm AIHA, while the complement-focused reports are small and mainly show what happened in a few individuals. [1] [2] [3]

In the ENERGY phase 2/3 randomized, double-blind trial in warm AIHA, nipocalimab (which lowers IgG antibodies) met the main goal only in the higher-dose group. A durable hemoglobin response was seen in 23.7% (9/38) on nipocalimab 30 mg/kg every 4 weeks compared with 7.7% (3/39) on placebo, while the 15 mg/kg schedule did not meet the primary endpoint by the study's criteria. [1]

In the same trial, the higher-dose nipocalimab group had nominal (not definitive) improvements in fatigue and a greater average reduction in prednisone use over 24 weeks compared with placebo, and no new safety concerns were reported beyond known risks. These results suggest that dose and schedule may matter, and that symptom and steroid outcomes still need confirmation in future work. [1]

Two small clinical reports described combining complement-blocking sutimlimab with immune-directed therapy in severe AIHA. In a three-person case series (two cold agglutinin syndrome and one warm AIHA/Evans syndrome), the authors reported rapid, durable remissions; two people stopped sutimlimab without relapse to date, and one remained in remission while continuing therapy, with one episode of severe neutropenia and infection requiring treatment. [2]

A separate one-person case report described cold agglutinin syndrome linked to chronic lymphocytic leukemia where sutimlimab rapidly stopped hemolysis and was used as a bridge while leukemia-directed treatment (obinutuzumab-venetoclax) was started. Hemoglobin normalized within 6 months and symptoms like fatigue and acrocyanosis improved, with no major adverse events reported in that individual. [3]

For patients and caregivers, these papers show two active directions in AIHA research: (1) trials of drugs designed to lower harmful antibodies in warm AIHA, with one dose showing clearer benefit than another in a controlled study, and (2) individualized use of complement-blocking therapy in severe cases, mainly supported by small reports. Right now, the trial results offer more reliable evidence than case reports, and important uncertainties remain about who benefits most, how durable responses are over longer periods, and how to balance benefits with infection and blood-count risks seen in some individuals.

The main message came from one detailed case: autoimmune hemolytic anemia (AIHA) can change over time, so the immune process driving a relapse may differ from earlier episodes. A separate study in multiple myeloma, not AIHA, found that a positive red blood cell antibody test (DAT) came with different lab and immune-cell patterns. Evidence ranges from a single-patient report (not generalizable) to a moderate-sized retrospective comparison in a different disease context. [4] [5]

In one woman in her 80s with mixed AIHA, a later relapse looked more complement-dominant even though an earlier abnormal CD20-positive cell population was no longer detectable in the bone marrow. After sutimlimab (a complement-pathway blocker), her hemoglobin rose without transfusion, along with recovery of complement marker C4 and suppression of total complement activity (CH50), while cold agglutinin activity remained present. [4]

That same case also described how repeat testing over time changed what was seen: IgG-kappa and IgM-kappa monoclonal proteins were identified later in the course, after the complement-dominant relapse. The report highlights that the immune drivers measured during one episode may not match what is driving a later relapse in the same person. [4]

In a retrospective study of 77 people with newly diagnosed multiple myeloma and anemia, those with a positive direct antiglobulin test (DAT) had different lab and immune-cell patterns than those with a negative DAT. The DAT-positive group more often had IgG-type M protein (88.46%), lower albumin and electrolytes, and higher globulin and ferritin, and they also showed higher lymphocyte counts with more CD8-positive T cells, while reduced NK-cell and B-cell counts were more common in the DAT-negative group. [5]

For patients and caregivers, this set of studies is mainly background on how doctors may describe AIHA subtypes and relapse patterns using repeat blood and immune testing, especially when the picture changes over time. The AIHA paper is one person and cannot predict what will happen in others, while the larger study was in multiple myeloma (not AIHA) but shows that a positive DAT can come with broader differences in inflammation-related labs and immune cells. What remains uncertain is how often AIHA shifts between immune mechanisms in real-world patients, and which specific lab changes best signal those shifts.

Across these papers, autoimmune hemolytic anemia (AIHA) appeared as an uncommon but important side effect of immune checkpoint inhibitors, a type of cancer immunotherapy. The overall message was that blood-related immune side effects are rare but can be serious, and AIHA may not always show up on standard antibody testing, which can make recognition harder. [6] [7]

In a systematic review focused on melanoma treatment, blood-related immune side effects were reported in under 4% of patients overall, but deaths were reported in the 12% to 15.5% range across blood-related immune complications. AIHA was listed among the most common blood-related immune problems, and combination immune checkpoint regimens were described as having more frequent and more severe toxicity than single-drug approaches. [6]

The same review noted that restarting immune checkpoint therapy after a severe blood-related immune side effect can lead to the problem coming back, and reported that recurrence is particularly high for AIHA, at roughly 50% to 78%, against about 14% to 43% for blood-related immune side effects generally. It also emphasized that workups may include blood tests for hemolysis and sometimes a bone marrow test to help separate red blood cell destruction in the bloodstream from problems with blood cell production. [6]

One case report described a 71-year-old woman with early-stage triple-negative breast cancer who developed early-onset AIHA during pembrolizumab-based chemotherapy around the time of surgery, with a negative direct antiglobulin (Coombs) test. Her anemia and hemolysis markers improved quickly after corticosteroids, pembrolizumab was stopped, and no recurrence of AIHA was reported in follow-up. As a single-patient report, it cannot predict how often this happens or who is most likely to experience it. [7]

For patients and caregivers, this set of papers mainly provides background context: AIHA and other immune-driven blood problems can occur during immune checkpoint therapy, even though they are uncommon. The review suggests these events can sometimes be severe, while the case report shows that AIHA can occur with a negative Coombs test and still improve after immune-suppressing treatment and stopping the checkpoint drug. What remains uncertain from these summaries is how to predict who will develop AIHA, how often Coombs-negative cases occur, and which evaluation steps matter most in each individual situation. [6] [7]

Across these papers, autoimmune hemolytic anemia (AIHA) and related immune blood count problems were described as complications that can happen after transplants or after certain medicines, and the course varied from mild to life-threatening. In the stem cell transplant series, first treatments worked for some but not all patients right away, and relapses happened, yet the group ultimately recovered without deaths directly due to the immune cytopenia. In the two single-patient reports, hemolysis developed in specific, identifiable situations (minor blood group mismatch after liver transplant, and repeated exposure to piperacillin-tazobactam), and improved after the trigger was addressed. [8] [9] [10]

In a single-center retrospective series of 16 people who developed autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation, responses to first-line treatment were mixed: 2 of 3 patients with AIHA responded, and 5 people had a recurrence. All 16 eventually responded to treatment, and the authors reported no deaths due to autoimmune cytopenia in this series. [8]

One case report described passenger lymphocyte syndrome (donor immune cells making antibodies) after an ABO-minor mismatched liver transplant, where hemolysis was supported by a positive direct antiglobulin test and detection of anti-B antibodies. The hemoglobin fell sharply (from 7.8 g/dL to 3.4 g/dL) and then stabilized after donor-type red blood cell transfusions and adjustments in immunosuppression, while hemolysis lab markers improved. [9]

Another case report described piperacillin-tazobactam drug-induced immune hemolytic anemia across three separate exposures in a woman with underlying liver disease that kept bilirubin levels high, which made interpretation harder. The second exposure caused severe hemolysis within 3 days (hemoglobin down to 5.8 g/dL) with an IgG-positive, C3d-negative direct antiglobulin test pattern; hemolysis improved after stopping the drug along with transfusion and corticosteroids. A later exposure lasted 6 days without hemolysis, showing that the pattern can be inconsistent even in the same person. [10]

For patients and caregivers, this set of studies mainly serves as background on situations where AIHA-like hemolysis can appear: after certain transplants and, more rarely, as an immune reaction to a specific drug. The strongest evidence here is a small single-center series after stem cell transplant showing varied early response and possible recurrence but no deaths attributed to the immune cytopenia, while the liver-transplant and antibiotic examples are single-patient reports that may not apply broadly. What remains uncertain is how often these events happen in different transplant settings, which people are most at risk, and why some episodes recur or differ across repeat exposures.

Across two single-patient reports, autoimmune hemolytic anemia (AIHA) appeared in the setting of broader autoimmune illness, including lupus-related disease and Sjogren syndrome with evolving lupus features. In both situations, the key pattern was severe hemolysis detected by blood tests and then improvement after immune-suppressing treatment plus supportive care. Because these are case reports, they show what can happen in individuals but cannot predict how common this is or which approach works best for most people. [11] [12]

In a 25-year-old woman with Sjogren syndrome and developing lupus features, warm AIHA became fulminant, with hemoglobin dropping to 3.2 g/dL. After pulse-dose intravenous steroids, intravenous immune globulin (IVIG), and transfusion support, her hemolysis resolved and hemoglobin recovered to 11.0 g/dL by discharge, without needing rituximab or spleen removal in this report. The authors noted that some specialized testing to fully classify the AIHA type was not available. [11]

In a 35-year-old woman on hemodialysis for end-stage kidney disease from lupus nephritis, yellow discoloration of the dialyzer membrane during dialysis triggered evaluation and uncovered mostly unconjugated high bilirubin with intravascular hemolysis. After high-dose prednisolone and six additional dialysis sessions, hemolysis markers and bilirubin normalized and the discoloration resolved. The report also emphasized that this discoloration is not specific to hemolysis and can have other causes. [12]

For patients who already live with systemic autoimmune conditions such as lupus or Sjogren syndrome, these reports add context that AIHA can sometimes show up suddenly and severely, and may be recognized through patterns in lab tests (for example bilirubin, LDH, and haptoglobin) or unexpected clues during care (such as changes seen during dialysis). The information mainly serves as background about real-world presentations and monitoring challenges, because it comes from individual cases and does not establish how often this occurs or which treatments are best overall.

Across a small case series and a small cohort description, AIHA appeared as one of several autoimmune complications in inherited combined immunodeficiencies, including Wiskott-Aldrich syndrome. The overall pattern was that AIHA in this context can be difficult to treat and may occur alongside other immune problems, infections, and low platelet counts. Evidence here is limited by small numbers and observational reporting, so it cannot show which treatments work best or how to prevent episodes. [13] [14]

A case series of three patients with genetic combined immunodeficiencies described severe, refractory AIHA developing after rhinovirus infection and not responding to standard first-line therapy. Care escalated to multi-step combinations (including steroids, IVIG, rituximab, sirolimus, plasma exchange, and in some cases spleen removal and other targeted agents), with one patient dying from intraventricular hemorrhage and two reaching hematologic stabilization over time. The authors highlighted that responses could not be tied to any single medication because many were used together. [13]

In a Moroccan cohort of 10 males with genetically confirmed Wiskott-Aldrich syndrome, autoimmune complications were reported in 2 of 10 patients, including AIHA and a lupus-like illness. Most patients relied on supportive care, and one patient who received a stem cell transplant was reported to have sustained remission, while another patient died from severe respiratory infection. The study focused on describing features of the disorder rather than testing a specific AIHA treatment plan. [14]

These studies are most relevant for families affected by inherited immunodeficiency disorders, where AIHA may be part of a broader immune and infection-related picture and can sometimes be prolonged or resistant to initial therapies. For most people with AIHA who do not have a known genetic immunodeficiency, this information is mainly background and helps explain why AIHA can look different depending on underlying immune conditions. Many uncertainties remain, including how often viral infections trigger AIHA in these disorders and which treatment combinations are most effective and safest.

Across these reports, immune-related hemolysis appeared alongside other uncommon immune problems affecting the gut or blood clotting, and careful testing helped clarify what was happening. Because all evidence here comes from single-patient (or single-animal) case reports, it shows what can happen but cannot tell how often it happens or what usually works.

One report described a 23-year-old man with a rare genetic inflammatory condition (PSTPIP1-associated syndrome) who had colitis that looked like inflammatory bowel disease and also had high zinc levels and enlarged liver and spleen. Treatment with adalimumab led to symptom and scope improvement by 6 months and complete healing by 12 months, along with hemoglobin, zinc, and inflammation markers moving toward normal, while low white blood cells persisted. [15]

Another report described an 80-year-old woman with autoimmune hemolytic anemia who developed a separate autoimmune problem that caused very low factor V (a clotting protein) due to rapid clearance. Standard clotting tests stayed very abnormal despite corticosteroids and plasma infusion, but newer whole-blood clot tests and thrombin generation testing suggested her clotting function was adequate and helped support a safe endoscopic procedure; anti-factor V IgG testing helped confirm the cause. [16]

A veterinary case report described a 4-month-old foal with Rhodococcus equi infection and severe anemia thought to fit an immune-mediated hemolytic process, along with disease outside the lungs. Despite intensive antibiotics and supportive care, the foal worsened and was euthanized, and a postmortem examination was performed. [17]

For patients and caregivers, these reports mainly serve as background information about rare, sometimes overlapping immune conditions that can occur alongside hemolysis, including gut inflammation or unusual bleeding-factor problems. They also highlight that, in specific situations, specialized lab testing may add information beyond standard blood tests, but it remains uncertain how broadly these approaches apply because each report describes only one case.